Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: pde 4
1,625 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

MDL 27,032 [4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone] is a novel vasodilator whose mechanism of action has not been elucidated. We investigated whether smooth muscle relaxation by MDL 27,032, in vitro, may involve an alteration in the activity of protein kinase C, cyclic AMP (cAMP)-dependent protein kinase or myosin light chain kinase by investigating the effects of MDL 27,032 on cyclic nucleotide phosphodiesterases (PDEs) and protein kinase activities. Strips of dog femoral artery or saphenous vein contracted with phorbol 12-myristate 13-acetate (PMA) were relaxed by 100 microM concentrations of MDL 27,032, as well as by other known inhibitors of PDEs [3-isobutyl-1-methylxanthine and papaverine], myosin light chain kinase (W-7) and protein kinase C (H-7 and polymyxin B). In contrast to 3-isobutyl-1-methylxanthine and papaverine, MDL 27,032 was either inactive or weak as an inhibitor of purified PDE types I, II, IVa and IVb. Similarly, it was a weak inhibitor of myosin light chain kinase. However, MDL 27,032 was a significantly more potent inhibitor of protein kinase C and cAMP-dependent protein kinase in cytosolic extracts of dog vein. Kinetic experiments utilizing purified rat brain protein kinase C revealed that inhibition with MDL 27,032 was competitive with Mg(++)-ATP (Ki 24 microM) and noncompetitive with phospholipid, diacylglycerol, PMA, calcium or substrate proteins. Inhibition of the catalytic subunit of cAMP-dependent protein kinase was also competitive with Mg(++)-ATP (Ki 14.3 microM). Similar results were obtained with MDL 27,032 and H-7 on both enzymes.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:MDL 27,032 [4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone], an active site-directed inhibitor of protein kinase C and cyclic AMP-dependent protein kinase that relaxes vascular smooth muscle. 217 6

The aim of this study was to investigate the effects of dietary calcium and sodium on blood pressure (BP) in normotensive rats (Wistar, WKY), spontaneously hypertensive rats (SHR) and Dahl rats and on calmodulin (CaM) activator, a newly-discovered hydrophobic compound that increases CaM activity in SHR and spontaneously hypertensive mice (SHM) tissues (J Clin Invest 82:276, 1988). The CaM activator was assessed by its capacity to stimulate a CaM-dependent phosphodiesterase (CaM-PDE). In Wistar rats, which were fed a high sodium diet (3.5%), BP significantly increased (P less than .01) from 106 +/- 4 to 128 +/- 8 mm Hg in parallel to an elevation of the CaM activator from 1.57 +/- 0.14 to 2.80 +/- 0.18 U. WKY, SHR, and Dahl salt-sensitive (DS/JR) and salt-resistant (DR/JR) rats were given low (0.15%) or high (2.5%) Ca diets, both with 1% sodium. In rats receiving high dietary Ca the progression of hypertension diminished and BP was lower in SHR (156 +/- 4 mm Hg) and young DS/JR rats (125 +/- 3 mm Hg) than in those receiving low dietary Ca (192 +/- 10 and 183 +/- 2 mm Hg). There was a concomitant decrease of CaM activator in these animals to levels indistinguishable from those of WKY or DR/JR rats. The activator was also found in the heart, kidneys and erythrocytes from SHM. In the presence of exogenously added CaM, lipidic extracts from the SHM heart showed augmented CaM-PDE activity relative to normotensive preparations. This difference was eliminated by trifluoperazine.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Increase of calmodulin activator in hypertension. Modulation by dietary sodium and calcium. 222 70

Flavonoids are a vast group of natural substances, but their pharmacological properties have not all been explored. The term flavonoid is used at large to designate a series of more than 4,000 molecules, which in fact can have very heterogenous molecular structures. We have shown that some flavonoids are good inhibitors of cyclic nucleotide phosphodiesterase (PDE). The most active PDE inhibitors among the flavonoids were also good inhibitors of the aggregation of human platelets in vitro. This suggests that flavonoids could serve as a template for the development of new anti-platelet drugs. However, a direct extrapolation of our experimental results to possible therapeutical use of flavonoid-containing medicinal plant extracts is not possible. The metabolic fate of these plant flavonoids is poorly understood, and their absence of toxicity has not always been clearly demonstrated. Flavonoids are also present in a regular diet in significant amounts. The role of these dietary flavonoids in the prevention of thrombotic diseases or atherosclerosis should also be investigated.
...
PMID:[Flavonoids: antithrombotic agents or nutrients?]. 227 80

1,4-Bis(3-oxo-2,3-dihydropyridazin-6-yl)benzene and a series of related bis(azinone) compounds were synthesized. These novel compounds were evaluated for inhibition of the low Km, cAMP-selective, cGMP-inhibited phosphodiesterase (PDE III) derived from cat heart and hemodynamic activity in the ganglion- and beta-blocked anesthetized cat. The most potent PDE III inhibitor of the series was 6-[4-(5-methyl-3-oxo-2,3,4,5-tetrahydropyridazin-6-yl)-phenyl]p yridazin- 3(2H)-one (IC50 = 0.07 microM), which also retained the greatest inotrope and vasodilator (inodilator) potency (ED50 for first derivative of left ventricular pressure (dLVP/dt(max)) = 0.02 mumol/kg, ED15 for 15% fall in perfusion pressure = 0.01 mumol/kg). The structure-activity relationships observed within the bis(azinone) series were consistent with those reported for formally analogous 6-(4-substituted-phenyl)pyridazin-3(2H)-one-based PDE III-inhibiting inodilators with less-extended phenyl substituents (see e.g. Sircar et al. J. Med. Chem. 1987, 30, 1955, Moos et al. J. Med. Chem. 1987, 30, 1963). PDE III inhibitory potency is associated with overall planar topology of the phenylpyridazinone moiety and the presence of two critically separated electronegative centers. A methyl group at the 5-position of a dihydropyridazinone ring leads to enhanced potency. However, the generally higher levels of PDE III inhibitory potency shown by compounds in the bis(azinone) series relative to earlier 6-(4-substituted-phenyl)pyridazin-3(2H)-one derivatives appears to derive from a closer to optimal separation of two interacting points in the inhibitor molecule achieved through the more extended bis(azinone) structure. Correlation between the pharmacological and PDE III inhibitory activities of compounds in the bis(azinone) series provides additional evidence for PDE III being an important mediator of inodilator action.
...
PMID:1,4-bis(3-oxo-2,3-dihydropyridazin-6-yl)benzene analogues: potent phosphodiesterase inhibitors and inodilators. 234 68

Maximal histamine release (HR) from leucocytes, in response to Concanavalin A (Con A) was significantly higher in a group of 16 adults with moderate to severe atopic dermatitis (AD) when compared to 13 non-atopic adults. In a further 4 adults with AD, HR was similar to that in the normals, suggesting the existence of 'high releaser' and 'low releaser' subsets within the AD group. Leucocyte cyclic AMP phosphodiesterase (PDE) activity was significantly higher in the 'high releaser' group compared to the 'low releaser' and normal groups. High and low HR responses showed strong correlations with high and low PDE. Pre-treatment of leucocytes from 'high releasers' with the experimental PDE PDE inhibitor RO-20-1724 reduced the HR to normal levels. These findings suggest that increased histamine 'releasability' in AD is related to abnormalities in cyclic nucleotide regulation. No significant HR could be demonstrated in response to a range of concentrations of methacholine in 'high releaser' atopics and normals. Methacholine also did not affect HR in response to maximal Con A stimulation in 'high releaser' atopics. Basophil percentages within the leucocyte preparation and the histamine content per basophil, were not significantly different between the atopics and normals. Con A-stimulated histamine release did not correlate significantly with serum IgE levels.
...
PMID:Basophil histamine release in atopic dermatitis and its relationship to disordered cyclic nucleotide metabolism. 240 32

The mechanism of the inotropic effect of piroximone HCl [MDL 19205A, 4-ethyl-1,3-dihydro-5-(4-pyridinylcarbonyl)-2H-imidozol-2-on e HCl] was studied in the cat papillary muscle paced electrically in vitro. Piroximone produced a concentration-dependent positive inotropic effect accompanied by an increase in rate of contraction and rate of relaxation, but abbreviated time to peak tension and relaxation time. The positive inotropic effect produced by piroximone was antagonized by carbachol, 3 X 10(-6) M, whereas that produced by increasing calcium concentration was not affected by carbachol. In potassium chloride (22 mM) depolarized muscle, piroximone restored contractility, which was not affected by propranolol (10(-6) M) or by tetrodotoxin (2 X 10(-5) M), but was inhibited by nifedipine (10(-7) M). Piroximine also elevated tissue cyclic AMP (cAMP) content in the papillary muscle. Although nifedipine inhibited the restoration of contractility, it did so without altering the increase of cAMP produced by piroximone. These results suggest that piroximone causes an increase in calcium influx that is mediated by an increase in cAMP, and the results are consistent with the hypothesis that specific inhibition of the high affinity cAMP phosphodiesterase (PDE III) plays a role in the positive inotropic effect of piroximone.
...
PMID:Studies on the mechanism of the positive inotropic effect of piroximone in cat papillary muscle. 241 Jul 17

In order to examine a possible contribution of cyclic AMP to acetylcholine (ACh) release from guinea pig ileum myenteric plexus, effects of adenylate cyclase inhibitors, phosphodiesterase (PDE) inhibitors and dibutyryl cyclic AMP on the spontaneous and the various stimuli-induced ACh release were investigated. A PDE inhibitor, theophylline (1 mM) increased the ACh release induced by nicotine (6.16 microM) significantly. Another PDE inhibitor, 3-isobutyl-1-methylxanthine (IBMX, 1 mM) and dibutyryl cyclic AMP (4 mM) had no effect. The adenylate cyclase inhibitors dithiobisnitrobenzoic acid (DTNB, 1 mM) and alloxan (4 mM) both decreased the nicotine-induced ACh release remarkably. PDE inhibitors increased and adenylate cyclase inhibitors decreased the high-K+-induced ACh release. Dibutyryl cyclic AMP brought about a slight but significant increase of the high-K+-induced ACh release. All the drugs failed to alter the ACh release induced by electrical field stimulation (EFS) at 10 Hz. Effects of all drugs except dibutyryl cyclic AMP on the spontaneous ACh release were the same as those on the nicotine-induced one. Dibutyryl cyclic AMP decreased it significantly. These results suggest that the cyclic AMP system is involved in the spontaneous, the nicotine-induced and the high-K+-induced ACh release and that the EFS-induced ACh release is independent of cyclic AMP.
...
PMID:Effects of adenylate cyclase inhibitors, phosphodiesterase inhibitors, and dibutyryl cyclic AMP on spontaneous and various stimuli-induced acetylcholine release from guinea pig ileum myenteric plexus. 241 37

The effects of pimobendan (UD-CG 115 BS) and UD-CG 212 Cl (2-(4-hydroxy-phenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6- pyridazinyl)benzimidazole X HCl) on force of contraction, beating frequency, and on adenylate cyclase and phosphodiesterase activity were investigated in isolated preparations from guinea-pig hearts. Both benzimidazole derivatives exerted a concentration-dependent positive inotropic effect in guinea-pig papillary muscles. The efficacies were similar to that of dihydroouabain. The positive inotropic effect of both benzimidazoles was accompanied by an enhancement of the rate of force development and a prolongation of the contraction. Both benzimidazole derivatives inhibited phosphodiesterase (PDE) activity in a crude preparation from guinea-pig ventricles. However, at the concentrations producing maximal positive inotropic effects in papillary muscles, pimobendan and UD-CG 212 Cl diminished PDE activity only by about 20-30%. Since both benzimidazoles did not affect adenylate cyclase in a particulate membrane preparation a stimulation of the cAMP synthesis can be ruled out. As recently reported for pimobendan, this study provides functional evidence that the positive inotropic effect of UD-CG 212 Cl is also at least partially mediated by cAMP. Firstly, the positive inotropic effect of UD-CG 212 Cl was inhibited by carbachol, adenosine and (-)-N6-phenyl-isopropyladenosine. Secondly, UD-CG 212 Cl potentiated the inotropic effects of isoprenaline and histamine. UD-CG 212 Cl had no positive chronotropic effect and pimobendan increased the beating frequency only slightly.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Effects of the benzimidazole derivatives pimobendan and 2-(4-hydroxy-phenyl)-5-(5-methyl-3-oxo-4,5-dihydro-2H-6- pyridazinyl) benzimidazole . HCl on phosphodiesterase activity and force of contraction in guinea-pig hearts. 241 46

We investigated the mechanisms of the direct positive inotropic effect (PIE) of helenalin, a sesquiterpene lactone isolated from the plant genus Helenium of the family Compositae in guinea pig ventricular myocardium. Helenalin (3 X 10(-4) M) produced biphasic PIEs (first and second PIE phases) on normal nonreserpinized papillary muscles, driven at 1 Hz in Krebs-Henseleit solution at 30 degrees C. The first PIE phase was abolished by reserpine treatment. Helenalin increased the force of "rested-state contraction" in a manner similar to that of other cyclic AMP-elevating substances, such as norepinephrine and IBMX (3-isobutyl-1-methylxanthine). In isometric contraction curves of the papillary muscle stimulated at 0.2 Hz, helenalin showed two clear peaks of an early and a late component. Carbachol preferentially suppressed the late component of contraction, a component that is clearly apparent in the presence of intracellular cyclic AMP-increasing substances. Helenalin potentiated the PIEs of isoproterenol and histamine but not that of dihydroouabain. In the presence of a phosphodiesterase (PDE) inhibitor (IBMX 10(-3) M), helenalin did not produce any PIE. In electrophysiological studies, helenalin prolonged the duration of transmembrane action potentials of papillary muscle. In partially depolarized muscles (external K+ = 30 mM), helenalin increased the overshoot and the duration of the slow action potential. These results led to the conclusion that helenalin produces an elevation of cyclic AMP through PDE inhibition, thereby increasing Ca2+ influx which enhances the contractility of the myocardium by increasing Ca2+ release from the SR.
...
PMID:Mode of cardiotonic action of helenalin, a sesquiterpene lactone, on guinea pig ventricular myocardium. 243 98

In immature follicular oocytes of the frog Xenopus laevis, application of muscarinic agonists evokes a complex response consisting of a fast and a slow Cl currents (the dominant responses), Cl current fluctuations, and a less prominent slow K current. The characteristics of the slow ACh-evoked potassium current were studied using the two-electrode voltage clamp method, and compared to those of the ACh-evoked Cl currents. In experiments designed to study the K current response separately, without the interference of ACh-evoked Cl currents, the holding potential was set close or equal to Cl equilibrium potential (measured as the reversal potential of the ACh-evoked Cl current). The Cl current responses were studied in cells that had negligible K current response. The dose-response curve of the potassium response followed classical Michaelis-Menten kinetics. The dose-response characteristics of the slow ACh-evoked Cl current displayed a positive cooperativity of at least 3. In spite of this difference, kinetic analysis revealed that these two responses, as well as the fast Cl current response that was characterized earlier (Dascal and Landau 1982), had almost identical apparent equilibrium dissociation constants (0.29-0.39 microM), suggesting involvement of a single receptor class. Both K and Cl currents were reduced (to 32-56% of control) by millimolar concentrations of phosphodiesterase (PDE) inhibitors, theophylline and isobutylmethylxanthine. Elevation of extracellular Ca concentration from 1 to 10 mM doubled the K current; depletion of external Ca caused a partial inhibition of this response. The K current was potentiated by 0.1 microM 4-phorbol 12,13-dibutyrate (PDBu).(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Further characterization of the slow muscarinic responses in Xenopus oocytes. 244 12


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>

---